AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 611325
Drug: Validation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Validation group (30 subjects) administered the Astrand‐Rhyming Test using the established multiple regression equation to predict workload.
Trial: 18808335
Drug: DNA priming
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA priming vaccine
Trial: 18808335
Drug: MVA boosting
RxNorm normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA boosting vaccine
Trial: 18808335
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of HIV‐1 DNA administered intradermally
Trial: 15770115
Drug: Sertraline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (150 mg/day)
Trial: 15367045
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (225 mg/day)
Trial: 17196045
Drug: Sertraline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (150 mg/day) at maximum dose for 3 weeks
Trial: 17196045
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (225 mg/day) at maximum dose for 3 weeks
Trial: 12689612
Drug: Fenfluramine administration
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine administration
Trial: 2440159
Drug: 250 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml Pentastarch
Trial: 2440159
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml Pentastarch
Trial: 2440159
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml Pentastarch
Trial: 2104531
Drug: Silicone cream
RxNorm normalized name: REMEDY SILICONE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone cream with 20% silicone oil and occlusive dressing technique
Trial: 2104531
Drug: Simple application
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple application of silicone cream
Trial: 6997360
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of anesthetic
Trial: 31030100
Drug: THD monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THD monotherapy
Trial: 16945121
Drug: Silodosin 4
RxNorm normalized name: silodosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 4 mg twice daily
Trial: 19531419
Drug: 2-g amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-g amoxicillin tablets 1 hour before surgery
Trial: 11141929
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic therapy (Control)
Trial: 7828613
Drug: SPET using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPET using technetium‐99m d,l‐hexamethylpropylene amine oxime (99mTc‐HMPAO)
Trial: 31656059
Drug: FENO-guided algorithm
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FENO-guided algorithm (inhaled corticosteroid (ICS) dose adjusted according to FENO with long-acting beta-agonist (LABA) added for uncontrolled symptoms)
Trial: 26136594
Drug: Serum 25(OH)D
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum 25(OH)D and plasma insulin concentrations
Trial: 20929998
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with nuts (30 g/day)
Trial: 17678911
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant FSH (75-150 IU/d) + GnRH antagonist (0.25 mg/d)
Trial: 16573259
Drug: Tazarotene 0.1%
RxNorm normalized name: TAZAROTENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tazarotene 0.1% cream plus clindamycin 1%/benzoyl peroxide 5% gel
Trial: 14574651
Drug: Severe smoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe smoke inhalation cases
Trial: 6382224
Drug: nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 20 mg twice a day
Trial: 6382224
Drug: mefruside 25
RxNorm normalized name: mefruside 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mefruside 25 mg once a day
Trial: 31829187
Drug: Organic rumen‐protected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organic rumen‐protected fat (RPF) supplement (0.45 kg/d)
Trial: 25556460
Drug: Nimotuzumab combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab combined with DCF chemotherapy
Trial: 25556460
Drug: Standard DCF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard DCF chemotherapy
Trial: 15951292
Drug: High-dose sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sequential (HDS) chemotherapy plus high-dose mitoxantrone and melphalan with autologous stem-cell transplantation (ASCT)
Trial: 15951292
Drug: Outpatient dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient dose-dense chemotherapy regimen (MegaCEOP)
Trial: 15951292
Drug: High-dose sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose sequential (HDS) chemotherapy plus ASCT
Trial: 7659407
Drug: 0.60% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.60% NaCl solution
Trial: 7659407
Drug: 0.45% NaCl
RxNorm normalized name: LVP solution Dextrose 5% with 0.45% NaCl intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% NaCl solution
Trial: 21210833
Drug: Er,Cr:YSGG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er,Cr:YSGG laser treatment
Trial: 16167748
Drug: Early feeding
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early feeding group (sips of water within 6-8 hours, followed by oral soup or milk at least 150 millilitres at a time within 8-12 hours post-operative)
Trial: 16167748
Drug: Routine feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine feeding group (restricted oral intake for 24 hours, administration of oral sips of water 24-48 hours post-operative)
Trial: 1347222
Drug: Nondepolarizing regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondepolarizing regimen with doses ranging from approximately 1.5 to 6 times the ED95, with or without a priming dose
Trial: 2939008
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of probucol and colestipol (treatment group)
Trial: 30340627
Drug: Standard attentional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard attentional bias task (non-treatment)
Trial: 20116631
Drug: Virosome vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosome vaccine (n=43)
Trial: 20116631
Drug: Split vaccine
RxNorm normalized name: INFLUENZA VIRUS,TRIVALENT SPLIT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split vaccine (n=47)
Trial: 18590393
Drug: Preoperative nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative nerve block (NB) with 0.25% 5‐8 ml bupivacaine mixed with 20‐40 mg methylprednisolone
Trial: 12468165
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg)
Trial: 7671159
Drug: Sodium ethiodronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ethiodronate 400 mg p.o., 15 days every 3 months (n = 23)
Trial: 2248063
Drug: Moclobemide (reversible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (reversible inhibitor of monoamine oxidase-A)
Trial: 29718385
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 (10 mg)
Trial: 29718385
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 (25 mg)
Trial: 29718385
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 (50 mg)
Trial: 29718385
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 409306 (100 mg)
Trial: 8471409
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vanoxerine after fasting
Trial: 8471409
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vanoxerine after low-fat meal
Trial: 3803702
Drug: Esaprazole 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaprazole 600 mg
Trial: 20819587
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (r-Sak or rt-PA)
Trial: 20819587
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy with rescue PCI
Trial: 8894721
Drug: Trapezius microcurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trapezius microcurrent therapy
Trial: 1815069
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 100 mg sulpiride
Trial: 1815069
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 100 mg sulpiride
Trial: 6404341
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose prednisolone (33 patients)
Trial: 6404341
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose prednisolone (34 patients)
Trial: 30505604
Drug: Metoprolol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (0.1 mg kg‐1) and tramadol (1 mg kg‐1)
Trial: 30505604
Drug: Remifentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.5 μg kg‐1 bolus followed by 0.25‐0.5 μg kg‐1 min‐1 infusion)
Trial: 23834392
Drug: Combined inhalation
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined inhalation of beta2-agonists (salbutamol, formoterol, salmeterol)
Trial: 19464026
Drug: Pramlintide (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (both doses)
Trial: 11801508
Drug: Unoprostone twice
RxNorm normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unoprostone twice daily
Trial: 9695964
Drug: Interferon alpha,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha, 3 x 10(6) units/m2 subcutaneously three times weekly until relapse
Trial: 7986464
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice daily (n = 77)
Trial: 7986464
Drug: Nicardipine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 50 mg twice daily (n = 77)
Trial: 16396765
Drug: High-dose mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose mitoxantrone combined with once daily cytarabine
Trial: 14700448
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) strategies, including maximally tolerated doses, switching medications, combining dissimilar medications, and combining psychotherapy with medication.
Trial: 14700448
Drug: Monotherapy (current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (current first-line standard of care)
Trial: 12374491
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 300 mg/d
Trial: 12374491
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 600 mg/d
Trial: 12374491
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 1200 mg/d
Trial: 9879213
Drug: Conventional (panoramic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional (panoramic + intra-oral radiographs)
Trial: 8026236
Drug: 90-ml oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90-ml oral sodium phosphate preparation
Trial: 8026236
Drug: 4-liter polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-liter polyethylene glycol solution
Trial: 8026236
Drug: sulfate-free 4-liter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfate-free 4-liter polyethylene glycol solution
Trial: 2607910
Drug: Fentanyl 3
RxNorm normalized name: FENTANYL 37.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 3 ug/kg plus aminophylline 3 mg/kg iv
Trial: 31876900
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg weekly or every 2 weeks
Trial: 26454361
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 4 weeks
Trial: 31876900
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 8 weeks
Trial: 20490797
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg/m²/day for five consecutive days per week for 1 year)
Trial: 17077073
Drug: HMB (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMB (3 g/d for 7 days)
Trial: 14656658
Drug: Anterolateral (A‐L)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterolateral (A‐L) THA
Trial: 14656658
Drug: Posterolateral (P‐L)
RxNorm normalized name: p-L-Sarcolysin
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Posterolateral (P‐L) THA
Trial: 14656658
Drug: Total THA
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total THA patients (A‐L and P‐L combined)
Trial: 11500188
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (lisinopril)
Trial: 9228228
Drug: Ebastine 10
RxNorm normalized name: ebastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebastine 10 mg or 20 mg
Trial: 26063762
Drug: Pharmacist prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist prescribing (assessment of BP and cardiovascular risk, education on hypertension, prescribing of antihypertensive medications, laboratory monitoring, and monthly follow-up visits for 6 months)
Trial: 18583285
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 300 mg/day
Trial: 18583285
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 300 mg/day + Clopidogrel 75 mg/day
Trial: 16567982
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 9VPCV
Trial: 16567982
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 9VPCV
Trial: 14576714
Drug: Video lessons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video lessons (self-administered, video-lesson packets)
Trial: 11089626
Drug: Circumcision in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumcision in HIV-positive men with viral loads <50,000 copies/ml
Trial: 1333181
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg subcutaneous sumatriptan
Trial: 1333181
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg subcutaneous sumatriptan
Trial: 1322512
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg subcutaneous sumatriptan
Trial: 1333181
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg subcutaneous sumatriptan
Trial: 3881206
Drug: timolol, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol, 1 mg iv, followed by 1 mg doses at 20-min intervals
Trial: 30614406
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (daily routines)
Trial: 11923548
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP) 750 microg bd
Trial: 8596749
Drug: rHuEPO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEPO therapy for 12 months
Trial: 8834648
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (No-EPO group)
Trial: 786961
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (400 mcg/day)
Trial: 27998692
Drug: Squill Oxymel
RxNorm normalized name: Squill oxymel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Squill Oxymel (10ml syrup, 2 times a day)
Trial: 27998692
Drug: Simple oxymel
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple oxymel (10ml syrup, 2 times a day)
Trial: 25787895
Drug: DC loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC loaded with recombinant Prostate Specific Membrane Antigen (rPSMA) and recombinant Survivin (rSurvivin) peptides administered as a subcutaneous (s.c.) injection (5×10(6) cells)
Trial: 25787895
Drug: Docetaxel (75 mg/m(2)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m(2) intravenous (i.v.)) and prednisone (5 mg, bis in die (b.i.d.))
Trial: 21827648
Drug: Supervised walks
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supervised walks of 30 minutes a day, 5 days a week as part of daily nursing care.
Trial: 19413409
Drug: Patch treatment
RxNorm normalized name: DIMETHICONE 1.1 g in 100 mL TOPICAL LOTION [Dove DermaSeries Rough Patch Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch treatment for smoking cessation
Trial: 11180023
Drug: Rofecoxib 12.5
RxNorm normalized name: rofecoxib 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 12.5 mg
Trial: 11188492
Drug: Daily positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily positive and negative affect
Trial: 11188492
Drug: Daily nonwork
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nonwork events (positive and negative)
Trial: 11188492
Drug: Daily work
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily work events (positive and negative)
Trial: 11188492
Drug: Lifetime symptoms
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifetime symptoms of alcohol dependence and treatment condition
Trial: 9195351
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg i.v. propofol bolus followed by a continuous 0.5 mg/kg/hr infusion
Trial: 1540108
Drug: Competing response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Competing response therapy (performing a competing response when the urge to bite occurs)
Trial: 2870990
Drug: Nifedipine combined
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine combined with propranolol (80 mg twice daily)
Trial: 2870990
Drug: Nifedipine combined
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine combined with betaxolol (20 mg once daily)
Trial: 2870990
Drug: Propranolol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol alone (80 mg twice daily)
Trial: 2870990
Drug: Betaxolol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol alone (20 mg once daily)
Trial: 31755587
Drug: S‐ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐ibuprofen
Trial: 31755587
Drug: R‐ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐ibuprofen
Trial: 27031099
Drug: Biweekly acupuncture
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly acupuncture treatments for 6 months (group 1)
Trial: 27031099
Drug: Weekly acupuncture
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly acupuncture treatments after 2 months of waitlist (group 2)